RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: a post hoc analysis of the GeparOLA trial
The randomized GeparOLA trial reported comparable pathologic complete response (pCR) rates with neoadjuvant treatment containing olaparib versus carboplatin. In this study, we evaluate the association between functional homologous recombination deficiency (HRD) by RAD51 foci and pCR and the potentia...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 March 2025
|
| In: |
Clinical cancer research
Year: 2025, Jahrgang: 31, Heft: 5, Pages: 808-814 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-24-3148 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-24-3148 Verlag, lizenzpflichtig, Volltext: https://aacrjournals.org/clincancerres/article/31/5/808/751947/RAD51-Testing-in-Patients-with-Early-HER2-Negative 
|
| Verfasserangaben: | Guillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, Andrea Herencia-Ropero, Peter A. Fasching, Thomas Karn, Frederik Marmé, Peter Klare, Volkmar Müller, Andrea Stefek, Christian Schem, Christoph Uleer, Tanja Fehm, Gabriele Doering, Elmar Stickeler, Marion van Mackelenbergh, Bärbel Felder, Valentina Nekljudova, Judith Balmaña, Carsten Denkert, Sibylle Loibl, and Violeta Serra |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1928320872 | ||
| 003 | DE-627 | ||
| 005 | 20250618114611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250617s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-24-3148 |2 doi | |
| 035 | |a (DE-627)1928320872 | ||
| 035 | |a (DE-599)KXP1928320872 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Villacampa, Guillermo |e VerfasserIn |0 (DE-588)1368891772 |0 (DE-627)192832133X |4 aut | |
| 245 | 1 | 0 | |a RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency |b a post hoc analysis of the GeparOLA trial |c Guillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, Andrea Herencia-Ropero, Peter A. Fasching, Thomas Karn, Frederik Marmé, Peter Klare, Volkmar Müller, Andrea Stefek, Christian Schem, Christoph Uleer, Tanja Fehm, Gabriele Doering, Elmar Stickeler, Marion van Mackelenbergh, Bärbel Felder, Valentina Nekljudova, Judith Balmaña, Carsten Denkert, Sibylle Loibl, and Violeta Serra |
| 264 | 1 | |c 1 March 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 3. März 2025 | ||
| 500 | |a Gesehen am 17.06.2025 | ||
| 520 | |a The randomized GeparOLA trial reported comparable pathologic complete response (pCR) rates with neoadjuvant treatment containing olaparib versus carboplatin. In this study, we evaluate the association between functional homologous recombination deficiency (HRD) by RAD51 foci and pCR and the potential of improving patient selection by combining RAD51 and stromal tumor-infiltrating lymphocytes.This is a post hoc blinded biomarker analysis from the randomized GeparOLA trial. Patients with early-stage HER2-negative breast cancer and HRD assessed by Myriad MyChoice or BRCA1/BRCA2 mutations were randomized 1:1 to receive (i) paclitaxel plus olaparib or (ii) paclitaxel plus carboplatin, both followed by epirubicin/cyclophosphamide. Functional HRD was predefined as a RAD51 score ≤10% (RAD51-low).Overall, 90 of 97 (92.8%) samples were evaluable for RAD51 testing, and 72 of 90 (80.0%) were RAD51-low. The pCR rate in patients with RAD51-low tumors was 66.7% (48/72), whereas it decreased to 22.2% (4/18) in those with RAD51-high. In the multivariable model including clinicopathologic factors and treatment, the RAD51 score remained significantly associated with pCR (OR = 12.03; 95% confidence interval, 2.60-55.73; P = 0.002). Patients with RAD51-low and high stromal tumor-infiltrating lymphocytes in their tumors achieved a pCR rate of 75.0% (27/36). Similar results were observed for olaparib or carboplatin. In the exploratory disease-free survival analysis, no differences were observed between RAD51 groups (high vs. low: HR = 0.85; 95% confidence interval, 0.25-2.97).In a preselected population with HRD, according to a genetic test, RAD51 testing identifies patients with different pCR rates under PARP inhibitor-based or platinum-based therapies. Future biomarker-driven studies should consider this information to refine stratification factors and to improve patient selection. | ||
| 700 | 1 | |a Llop-Guevara, Alba |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filmann, Natalie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herencia-Ropero, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fasching, Peter A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Karn, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Klare, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Müller, Volkmar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stefek, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schem, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uleer, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fehm, Tanja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Doering, Gabriele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stickeler, Elmar |e VerfasserIn |4 aut | |
| 700 | 1 | |a van Mackelenbergh, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Felder, Bärbel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nekljudova, Valentina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Balmaña, Judith |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denkert, Carsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 700 | 1 | |a Serra, Violeta |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 31(2025), 5, Seite 808-814 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency a post hoc analysis of the GeparOLA trial |
| 773 | 1 | 8 | |g volume:31 |g year:2025 |g number:5 |g pages:808-814 |g extent:7 |a RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency a post hoc analysis of the GeparOLA trial |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-24-3148 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://aacrjournals.org/clincancerres/article/31/5/808/751947/RAD51-Testing-in-Patients-with-Early-HER2-Negative |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250617 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 7 | ||
| 999 | |a KXP-PPN1928320872 |e 4734730253 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"language":["eng"],"disp":"RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency a post hoc analysis of the GeparOLA trialClinical cancer research","recId":"325489971","pubHistory":["1.1995 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"name":{"displayForm":["American Association for Cancer Research"]},"origin":[{"dateIssuedDisp":"1995-","publisher":"AACR","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995"}],"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"id":{"zdb":["2036787-9"],"issn":["1557-3265"],"eki":["325489971"]},"part":{"volume":"31","text":"31(2025), 5, Seite 808-814","year":"2025","pages":"808-814","extent":"7","issue":"5"},"physDesc":[{"extent":"Online-Ressource"}]}],"note":["Online veröffentlicht: 3. März 2025","Gesehen am 17.06.2025"],"physDesc":[{"noteIll":"Illustrationen","extent":"7 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1928320872"],"doi":["10.1158/1078-0432.CCR-24-3148"]},"language":["eng"],"title":[{"title":"RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency","title_sort":"RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency","subtitle":"a post hoc analysis of the GeparOLA trial"}],"person":[{"role":"aut","family":"Villacampa","display":"Villacampa, Guillermo","given":"Guillermo"},{"family":"Llop-Guevara","display":"Llop-Guevara, Alba","given":"Alba","role":"aut"},{"role":"aut","display":"Filmann, Natalie","given":"Natalie","family":"Filmann"},{"given":"Andrea","display":"Herencia-Ropero, Andrea","family":"Herencia-Ropero","role":"aut"},{"family":"Fasching","display":"Fasching, Peter A.","given":"Peter A.","role":"aut"},{"given":"Thomas","display":"Karn, Thomas","family":"Karn","role":"aut"},{"role":"aut","family":"Marmé","display":"Marmé, Frederik","given":"Frederik"},{"display":"Klare, Peter","given":"Peter","family":"Klare","role":"aut"},{"role":"aut","family":"Müller","display":"Müller, Volkmar","given":"Volkmar"},{"role":"aut","family":"Stefek","display":"Stefek, Andrea","given":"Andrea"},{"family":"Schem","given":"Christian","display":"Schem, Christian","role":"aut"},{"role":"aut","family":"Uleer","given":"Christoph","display":"Uleer, Christoph"},{"role":"aut","family":"Fehm","display":"Fehm, Tanja","given":"Tanja"},{"role":"aut","family":"Doering","given":"Gabriele","display":"Doering, Gabriele"},{"role":"aut","given":"Elmar","display":"Stickeler, Elmar","family":"Stickeler"},{"display":"van Mackelenbergh, Marion","given":"Marion","family":"van Mackelenbergh","role":"aut"},{"role":"aut","family":"Felder","display":"Felder, Bärbel","given":"Bärbel"},{"family":"Nekljudova","given":"Valentina","display":"Nekljudova, Valentina","role":"aut"},{"given":"Judith","display":"Balmaña, Judith","family":"Balmaña","role":"aut"},{"role":"aut","family":"Denkert","given":"Carsten","display":"Denkert, Carsten"},{"role":"aut","given":"Sibylle","display":"Loibl, Sibylle","family":"Loibl"},{"display":"Serra, Violeta","given":"Violeta","family":"Serra","role":"aut"}],"recId":"1928320872","name":{"displayForm":["Guillermo Villacampa, Alba Llop-Guevara, Natalie Filmann, Andrea Herencia-Ropero, Peter A. Fasching, Thomas Karn, Frederik Marmé, Peter Klare, Volkmar Müller, Andrea Stefek, Christian Schem, Christoph Uleer, Tanja Fehm, Gabriele Doering, Elmar Stickeler, Marion van Mackelenbergh, Bärbel Felder, Valentina Nekljudova, Judith Balmaña, Carsten Denkert, Sibylle Loibl, and Violeta Serra"]},"origin":[{"dateIssuedDisp":"1 March 2025","dateIssuedKey":"2025"}]} | ||
| SRT | |a VILLACAMPARAD51TESTI1202 | ||